Progressive Disorders

Andrew Hooker, Lena Friberg, Mats Karlsson,

Elodie Plan
 

Progressive neurological disorders such as Alzheimer’s disease and Parkinson’s disease represent challenges in many respects. The slow progression may make it difficult to assess in which aspect -a disease-modifying or symptomatic manner- the treatment impacts the disease. How to best design and analyse trials in these disorders, but also for diseases with relapsing progression patterns such as Multiple Sclerosis and Schizophrenia, are the topics of our investigations.

Further, the severity of most of these diseases are followed over time using clinical scoring scales that are formed from tests or questions probing individual aspects of the disease. Rather than using the overall clinical scale, we are developing methodologies and models based on item response theory (IRT), where each item (i.e. test or question) is modelled individually as a function of a latent variable of the disease-related disability.